eligibility_summary
Adults (>=18) with CD20+ indolent B-cell lymphoma (FL grade 1-3a, MZL incl. SMZL/gastric, WM/LPL, HCL-v) needing systemic therapy, ECOG 0-2, measurable disease, life expectancy >=3 mo, adequate blood/renal/hepatic function, contraception required. Exclude prior lymphoma chemo/immunotherapy/radiation, transformed/aggressive disease, CNS involvement, drug/murine allergy, HBV/HCV/HIV/HTLV1+, major comorbidities, active infection, other cancers (<5y), pregnancy, recent trials/steroids/live vaccines, PML, transplant.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm study in newly diagnosed indolent mature B‑cell lymphomas (FL, MZL, WM/LPL, HCL‑v). Induction: obinutuzumab + bendamustine, responders receive 2‑year obinutuzumab maintenance. Obinutuzumab is a type II, glycoengineered humanized anti‑CD20 IgG1 monoclonal antibody (immunotherapy) that depletes CD20+ B cells via enhanced antibody‑dependent cellular cytotoxicity/phagocytosis and direct cell death (limited complement activation). Bendamustine is an alkylating agent (nitrogen mustard) with antimetabolite properties that forms DNA crosslinks, causing DNA damage and apoptosis. Targets/pathways: CD20 on mature B lymphocytes, Fcγ receptor–mediated effector cells (NK cells/macrophages) for ADCC/ADCP, DNA damage response and apoptotic pathways in malignant B cells. Aim: improve outcomes with induction plus obinutuzumab maintenance.